Kater, Arnon P <br/><br/>
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.  [electronic resource] 

 -  Blood advances  12 2018 
 - 3566-3571 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2473-9537 
<br/><br/><label>Standard No.: </label>10.1182/bloodadvances.2018019422  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Bridged Bicyclo Compounds, Heterocyclic--therapeutic use<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual<br/>Remission Induction<br/>Risk Factors<br/>Sulfonamides--therapeutic use<br/>Tumor Lysis Syndrome--etiology